# Network contract directed enhanced service

Guidance for 2025/26 in England

Part A: Clinical and support services (Section 8)



Contents

[1. Introduction 3](#_Toc193808063)

[2. Service requirements 3](#_Toc193808064)

[2.1 Improving health outcomes and reducing health inequalities 4](#_Toc193808065)

[Population health management 4](#_Toc193808066)

[Health inequalities 4](#_Toc193808067)

[CVD prevention and diagnosis 5](#_Toc193808068)

[Early cancer diagnosis 8](#_Toc193808069)

[2.2 Targeting resource and efforts 10](#_Toc193808070)

[Proactive care (for frailty) 10](#_Toc193808071)

[Structured medication reviews (SMRs) and medicines optimisation 10](#_Toc193808072)

[Social prescribing 13](#_Toc193808073)

[Enhanced health in care homes (EHCH) 15](#_Toc193808074)

[3. Enhanced access 16](#_Toc193808075)

[Delivery of enhanced access 16](#_Toc193808076)

[Funding for enhanced access in the Network Contract DES 17](#_Toc193808077)

[4. Appendix 17](#_Toc193808078)

[Coding requirements – SNOMED codes 17](#_Toc193808079)

1. Introduction

The Network Contract Directed Enhanced Service (DES) was introduced during 2019. For 2025/26, the Network Contract DES Specification come into force on 1 April 2025 and, following participation in the DES, the requirements on practices and primary care networks (PCNs), as outlined in the DES specification, will apply from that date.

NHS England announced a number of changes to the DES from 2024/25 in order to support PCNs by streamlining requirements and increasing clinical autonomy over how to improve care.

This document forms part of a ‘guidance’ package designed to support commissioners, PCNs and their constituent practices to implement the DES. It does not take precedence over the DES specification. It includes:

descriptions of best practice in support of the delivery of the Section 8 ‘Service Requirements’ in the DES;

links to additional resources available to networks and practices;

an annex of SNOMED codes which should be used for recording of relevant activities

The part B guidance contains information on non-clinical service delivery matters for example, in relation to contract management and participation in the DES. This separate accompanying guidance can be found [here](https://www.england.nhs.uk/gp/investment/gp-contract/network-contract-directed-enhanced-service-des/).

1. Service requirements

The DES specifies that a PCN must deliver four key functions. Two of those functions relate to how the PCN organises and operates effectively:

* *“co-ordinate, organise and deploy shared resources to support and improve resilience and care delivery at both PCN and practice level.*
* *improve health outcomes for its patients through effective population health management and reducing health inequalities.*
* *target resource and efforts in the most effective way to meet patient need, which includes delivering proactive care; and*
* *collaborate with non-GP providers to provide better joined up care, as part of an integrated neighbourhood team."*

The rest of this section provides information in support of best practice delivery of the last two bullets. It also provides guidance on delivery of the enhanced access service specification.

### 2.1 Improving health outcomes and reducing health inequalities

#### Population health management

2.1.1 The DES specification states that “*a PCN must seek to improve health outcomes for its population using a data-driven approach and population health management techniques in line with guidance and the CORE20PLUS5 approach.”*

2.1.2 To achieve this PCNs should consider applying a population health management approach to service delivery. It can be visualised as improvement cycle [as shown on the futures.nhs.uk web page.](https://future.nhs.uk/populationhealth/view?objectID=160504357)

PCNs are expected to engage proactively with wider delivery partners including secondary, community, and mental health services partners and agree formal data sharing arrangements with ICBs to support local integration of data in line with the [What Good Looks Like Framework](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Ftransform.england.nhs.uk%2Fdigitise-connect-transform%2Fwhat-good-looks-like%2Fwhat-good-looks-like-publication%2F&data=05%7C01%7Cmiranda.flood1%40nhs.net%7C2ebf5f4a7f214e24e8ea08dbed1f7846%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638364491629783243%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=I%2B6aG9HU0SwcQ2s%2BZbuqsL5RLWtN9TUORz%2F9BG0s5gs%3D&reserved=0).

To use the data, a range of techniques can be used to understand and assess the needs of different population groups (segmentation, risk prediction, opportunity analysis, gaps in care). These are explained in the NHS England [Analytics Playbook](https://future.nhs.uk/populationhealth/view?objectId=156226917) and Imperial College Health Partners [How and Why to get started with Population Segmentation Analysis.](https://imperialcollegehealthpartners.com/getting-started-with-segmentation-analysis/) PCNs can expect to be supported by [ICB intelligence functions](https://www.england.nhs.uk/long-read/building-an-ics-intelligence-function/) in their approach and in using the data. E-learning modules on the principles of Population Health Management can be accessed at [the E-Learning for Health Hub.](https://www.e-lfh.org.uk/programmes/population-health-management/)

Additional resources include:

* The National Association of Primary Care (NAPC) describes a range of methods, including the [population cube](https://napc.co.uk/wp-content/uploads/2019/08/NAPC-Population-heath-guide-web.pdf). This can provide ways to visualise how PCNs might take a life-course approach to understanding the needs of different population groups.
* Guidance on [Logic Models](https://future.nhs.uk/system/login?nextURL=%2Fconnect%2Eti%2Fpopulationhealth%2Fview%3FobjectId%3D198422821) which may aid PCNs with planning how best to impact on their populations.
* Additional tools resources and case studies can be found at [Population Health Academy - Integrated Care (future.nhs.uk)](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Ffuture.nhs.uk%2Fpopulationhealth%2FgroupHome&data=05%7C02%7Canisa.varsani%40nhs.net%7Ce57f9554631241ac666c08dc00941cdc%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638385883326249908%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=vpCjeTVYoKglDgxwtEU%2FNdob3cEANmH45OhxyV5AGBw%3D&reserved=0).

#### Health inequalities

The DES specification states that a PCN should “*actively seek to reduce health inequalities across its Core Network Practices in line with guidance and the CORE20PLUS5 approach*.”

To achieve this a PCN should work in partnership within local communities to address health inequalities that are amenable to primary care interventions. The [CORE20PLUS5 approach](https://www.england.nhs.uk/about/equality/equality-hub/national-healthcare-inequalities-improvement-programme/core20plus5/) provides a helpful focal point for galvanising action and guiding targeting and outreach regarding conditions which disproportionately affect people from areas of greater deprivation. There is also a CORE20PLUS5 approach for the issues affecting [children and young people.](https://www.england.nhs.uk/about/equality/equality-hub/national-healthcare-inequalities-improvement-programme/core20plus5/core20plus5-cyp/)

Two of the five clinical areas set out in the of CORE20PLUS5 approach for adults focus on improving cardiovascular disease (CVD) prevention and diagnosis, and early cancer diagnosis. These are covered in more detail in the following section.

#### CVD prevention and diagnosis

The DES specification states that a PCN's approach must include: “*working with partners, including community pharmacy, to proactively identify and manage CVD risk hypertension and raised lipids in line with nationally agreed guidance and pathways.”*

To achieve this, there are practical actions and steps that PCNs can take:

| **Outcome** | **A PCN should:** |
| --- | --- |
| Improve detection and management of CVD risk factors. | * review outputs from CVD intelligence tools (including [CVDPREVENT](https://www.cvdprevent.nhs.uk/home)) and local population health datasets and share key learning amongst PCN staff;
* support the development of system pathways for people at risk of CVD through liaison with wider system partners;
* collaborate with commissioners to improve levels of diagnostic capacity for **A**trial fibrillation, **B**lood Pressure and **C**holesterol (known as the ‘ABC’ of CVD risk) testing, including availability of ambulatory blood pressure monitors (ABPMs) and electrocardiogram (ECG) monitors;
* ensure processes are in place to support the exchange of information with community pharmacies, including a process for accepting and documenting referrals between community pharmacies and GP practices for the [Community Pharmacy Blood Pressure Check Service](https://www.england.nhs.uk/primary-care/pharmacy/nhs-community-pharmacy-bp-checks-and-hypertension-case-finding-advanced-service/).
 |
| Improve the detection of hypertension | * offer appropriate follow-ups, including following [NICE guidance NG136](https://www.nice.org.uk/guidance/NG136) to ensure high blood pressure is followed up, and also proactively review historical records to identify patients who are not on the hypertension register, but whose last recorded BP was equal or higher than 140/90mmHg. In these scenarios, patients are expected to be offered a new blood pressure test plus diagnostic procedure (if needed) to confirm or exclude diagnosis of hypertension.
* undertake activity to improve the coverage of blood pressure checks including:
* increasing opportunistic blood pressure testing where patients do not have a recently recorded BP reading;
* undertake blood pressure testing at suitable outreach venues, agreeing the approach with local partners and informed by local data on health inequalities;
* work pro-actively with community pharmacies to improve access to blood pressure checks.
 |
| Improve the detection of atrial fibrillation | * follow [NICE guideline NG196,](https://www.nice.org.uk/guidance/ng196) to improve the identification of those at risk of atrial fibrillation through opportunistic pulse checks alongside blood pressure checks undertaken in a clinical setting, and ensuring the results are recorded and communicated to the GP practice alongside the BP reading.
 |
| Identify and manage raised lipids | **Cholesterol – primary and secondary prevention*** In line with [NICE NG238](https://www.nice.org.uk/guidance/ng238), where clinically appropriate and using a shared decision making approach, offer statin treatment and/or other lipid lowering therapies in line with [National Lipid Management Guidance](https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2020/04/lipid-management-pathway-v6.pdf), e.g.:
	+ - in primary prevention patients with a QRISK2or3 score ≥ 10%;
		- in all secondary prevention patients, aiming to achieve LDL-C</=2.0 mmol/l or non-HDL-C </= 2.6mmol/l.
* Statin intolerance is expected to be addressed in line with the [Statin Intolerance Pathway](https://www.england.nhs.uk/aac/publication/statin-intolerance-pathway/)
* work with the local authority to ensure uptake and delivery of the NHS Health Check is optimised for their population. Clinicians may identify patients using a range of validated tools, such as the UCL Partners Proactive Care Framework or CVDACTION
 |
| **Familial Hypercholesterolaemia (FH)*** use [NICE guidance CG71](https://www.nice.org.uk/guidance/NG136) to guide the identification of people at risk of familial hypercholesterolaemia;
* systematically search primary care records for those at highest risk, including people:
* younger than 30 years, with a total cholesterol concentration greater than 7.5 mmol/l; and
* 30 years or older, with a total cholesterol concentration greater than 9.0 mmol/l;

It is recommended that FH risk be assessed using Simon-Broome or Dutch Lipid Clinic Criteria; and where probable or possible FH is suspected, patients should be referred for further specialist assessment (where available) to include DNA testing in line with local pathways, which may be accessed via genomics hubs in some areas.  |
| Earlier identification of heart failure | * promote and facilitate the use of NT-proBNP amongst primary care clinicians, for people with symptoms or signs of heart failure, in line with [GPDA guidance;](https://www.england.nhs.uk/long-read/enhancing-gp-direct-access-to-diagnostic-tests-for-patients-with-suspected-chronic-obstructive-pulmonary-disease-asthma-or-heart-failure/)
* ensure that patients with suspected heart failure and a raised NT-proBNP are referred urgently for further assessment, in line with [NICE guideline NG106](https://www.nice.org.uk/guidance/ng106); and
* ensure coding is used as outlined in the appendix. Those who have confirmed heart failure should be coded according to accepted classification (following the results of an echocardiogram).
 |

#### Early cancer diagnosis

The DES specification also states that a PCN's approach must include: “*reviewing cancer referral practice in collaboration with partners and working to improve early diagnosis*” and "*working with partners to improve screening uptake, inclusive of breast, bowel and cervical cancer*.”

To achieve this a PCN should take actions to improve in line with the guidance below.

##### Improving referral practice

A PCN should work with Cancer Alliances to increase early diagnosis rates and improve referral practice. Alliances have been allocated funding to support this work. Together, PCNs and Alliances should develop a clear set of actions and milestones to improve referral practice for:

* Colorectal and lung cancer, which together account for nearly 40% of all late-stage cancer diagnoses; and,
* One other cancer type determined locally, based on burden of late-stage diagnoses and opportunities for timely and effective referral to support earlier diagnosis.

A PCN should also work with Alliances and its GP practices to:

* review the recommendations of, and ensure local referral practice reflects, [NICE Guideline NG12](https://www.nice.org.uk/guidance/ng12);
* audit referrals for people who have received a diagnosis of cancer. The following templates could be used to do this: [NCDA Patient Proforma](https://www.cancerresearchuk.org/sites/default/files/ncda_data_proforma_-_indivdiual_patients_0.docx) and [NCDA Data collection template](https://www.cancerresearchuk.org/sites/default/files/ncda_2014_datacollectiontemplate.xlsx);
* use [Office for Health Improvement and Disparities (OHID) Fingertips](https://fingertips.phe.org.uk/profile/cancerservices), which provides data on cancer services at GP practice and PCN level, to inform improvement actions; and,
* assess different stages in the pathway for improvement, for example, the interval between first presentation and when an urgent suspected cancer referral is made and the number of appointments prior to urgent suspected cancer referral.

Guidance has been updated to support and streamline diagnosis and referral practice in primary care. A PCN should:

* promote use of direct access tests where GPs consider an urgent investigation is required but do not think an urgent suspected cancer referral, as per NICE NG12 guidance, is appropriate, as outlined in [NHS England GP Direct Access guidance](https://www.england.nhs.uk/long-read/urgent-gp-direct-access-to-diagnostic-services-for-people-with-symptoms-not-meeting-the-threshold-for-an-urgent-suspected-cancer-referral/).
* promote use of Faecal Immunochemical Testing (FIT) to patients with signs and symptoms of colorectal cancer to identify those requiring a Lower GI Urgent Suspected Cancer referral. FIT testing should be delivered in accordance with [NICE Diagnostics Guidance 56](https://www.nice.org.uk/guidance/dg56). Patients living in more deprived areas are more likely to be diagnosed with bowel cancer at a later stage and are less likely to complete a FIT test. PCNs should target action to address variation in completion of FIT tests in symptomatic patients by deprivation and develop patient education and safety netting approaches to follow up with those who have not returned their FIT test.
* promote use of Non-Specific Symptom (NSS) pathways for patients with symptoms that could indicate cancer but who do not fit clearly into a single Urgent Suspected Cancer referral pathway. PCNs should support practices to undertake filter function tests for NSS patients, as outlined in Annex 1 of the [Faster Diagnosis Framework](https://www.england.nhs.uk/cancer/faster-diagnosis/).
* promote the use of teledermatology to support faster skin cancer referrals, with reference to NHS England [guidance](https://www.england.nhs.uk/wp-content/uploads/2022/04/B0829-suspected-skin-cancer-two-week-wait-pathway-optimisation-guidance.pdf) and the [Best Practice Timed Pathway](https://www.england.nhs.uk/wp-content/uploads/2018/04/B1350_Skin-cancer-timed-diagnostic-pathway.pdf).

##### Screening uptake

Actions to improve screening uptake should include:

* using data on OHID [Fingertips](https://fingertips.phe.org.uk/profile/cancerservices) to understand any variance in screening programme uptake and take corrective action;
* auditing non responders to the cancer screening programme/s, including breast, cervical and bowel, to analyse why uptake may be low and work with the NHS England regional public health commissioning teams, Cancer Alliances and ICBs to identify and action improvement priorities;
* adopting an [‘Every Contact Counts’](https://www.england.nhs.uk/publication/making-every-contact-count-mecc-consensus-statement/) approach ensuring screening history is checked at every appointment;
* making use of resources available to identify initiatives, including:
	+ [CRUK Primary Care Good Practice Guide: Cervical Screening](https://www.cancerresearchuk.org/sites/default/files/final_uk_cervical_screening_guide_july_21.pdf);
	+ [Macmillan Cancer Screening Quality Improvement Toolkit.](https://cdn.macmillan.org.uk/dfsmedia/1a6f23537f7f4519bb0cf14c45b2a629/1524-source/cancer-screening-tcm9-357843?_ga=2.203044883.36758942.1641821661-852643082.1632760364)
	+ [Healthcare professionals | Breast Cancer Now Resources for health professionals and patients](https://breastcancernow.org/information-support/healthcare-professionals);
	+ [Help Us Help You](https://campaignresources.dhsc.gov.uk/campaigns/help-us-help-you-cancer/) cancer screening campaigns;
	+ [Screening Saves Lives](https://screeningsaveslives.co.uk/professionals/) which can be delivered locally.
	1. Targeting resource and efforts

#### Proactive care (for frailty)

The DES specification states that PCNs “*must contribute to the delivery* [*of multi-disciplinary proactive care*](https://www.england.nhs.uk/community-health-services/proactive-care/) *for complex patients at greatest risk of deterioration and hospital admission, by risk stratifying patients and offering care in accordance with the guidance. This must be done as part of INTs, with the aim of reducing avoidable exacerbations of ill health, improving quality of care and patient experience, and reducing unnecessary hospital admission*.”

To achieve this, a PCN should refer to the [proactive care guidance](https://www.england.nhs.uk/long-read/proactive-care-providing-care-and-support-for-people-living-at-home-with-moderate-or-severe-frailty/) to identify and code the target cohort, develop a personalised care and support plan, deliver co-ordinated multi-professional interventions and provide a clear plan for continuity of care. Depending on local capacity to implement proactive care, further prioritisation may be needed based on risk of deterioration.

A PCN should utilise analysis of local data sets (as developed by ICS analytical teams where applicable), evidence-based risk prediction tools such as the [electronic frailty index](https://www.england.nhs.uk/ourwork/clinical-policy/older-people/frailty/efi/), the [EFI2 (when published](https://www.arc-nt.nihr.ac.uk/research/projects/improving-frailty-identification-in-primary-care/)), clinical validation tools and local knowledge, and practitioners should use the SNOMED codes outlined in the appendix.

#### Structured medication reviews (SMRs) and medicines optimisation

The DES specification states that PCNs must “*detail the measures a PCN will take to improve medicines optimisation and implement those measures, including ensuring medicines management and use of* [*Structured Medication Reviews*](https://www.england.nhs.uk/primary-care/pharmacy/smr/#:~:text=Structured%20Medicine%20Reviews%20(SMRs)%20are,all%20aspects%20of%20their%20health.) *for high-risk cohorts, as specified in the guidance. This should include medicines optimisation strategies for reducing polypharmacy, minimising risk of prescribing harm, reducing over-prescribing and managing the risk of dependency on prescription drugs*”.

To achieve this a PCN can undertake three priority actions as described below:

##### Identify patients suitable for an SMR

PCNs should use appropriate tools to identify and prioritise patients who they deem high risk from their population, and would benefit from a SMR, which is expected to include those people where there is evidence of benefit including, but not restricted to, those:

* in care homes;
* with learning disabilities;
* with complex and problematic polypharmacy, specifically those on 10 or more medications;
* on medicines commonly associated with [medication errors](https://www.nhsbsa.nhs.uk/sites/default/files/2019-08/Medication%20Safety%20-%20Indicators%20Specification%20%28Aug19%29.pdf) and [risk of harm](https://www.gov.uk/guidance/valproate-use-by-women-and-girls);
* with [severe frailty](https://www.england.nhs.uk/ourwork/clinical-policy/olderpeople/frailty/efi/) who are particularly isolated or housebound or who have had recent hospital admissions and/or falls;
* using one or more [medicines associated with dependence or withdrawal symptoms](https://www.nice.org.uk/guidance/ng215/resources/visual-summary-before-starting-medicines-associated-with-dependence-or-withdrawal-symptoms-pdf-11018567341), from the following groups: antidepressants; opioids; gabapentinoids; benzodiazepines; and Z-drugs.

PCNs should also be alert to the needs of communities and individuals at particular risk of health inequalities (eg CORE-20PLUS5 population, BAME, those with learning disabilities), including by considering how complex prescribing regimens may be rationalised to improve their safety.

PCNs should consider [NICE guidelines NG5](https://www.nice.org.uk/guidance/ng5) and the [Royal Pharmaceutical Society’s polypharmacy guidance](https://www.rpharms.com/recognition/setting-professional-standards/polypharmacy-getting-our-medicines-right), as well as the findings of [the National Overprescribing Review](https://www.gov.uk/government/publications/national-overprescribing-review-report), in identifying patients and determining their approach.

Once patients have been identified, PCNs should create a process for developing SMR caseloads so that those patients in greatest need of a SMR are seen in a timely manner.

The patient’s invitation to the SMR – whether oral or written – should explain what the SMR will involve, and that they will be coming in for a shared decision making conversation to review all their medications and make sure they are working well for them.

##### Conducting an SMR

Clinicians should conduct SMRs in line with the principles of [shared decision making and personalisation](https://www.england.nhs.uk/shared-decision-making/): [ensure the patient understands the purpose of the SMR appointment](https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/patient-information/), consider the health literacy and holistic needs of the patient, provide advice and signpost, and make onward referrals where appropriate, including to community pharmacies who all deliver healthy living pharmacy services to advise on evidence-based alternatives to medicines if appropriate. Community pharmacies can also support people newly started on medicines through the [NHS New Medicines Service](https://www.england.nhs.uk/primary-care/pharmacy/pharmacy-services/nhs-new-medicine-service/).

When undertaking an SMR, in addition to the principles of shared decision making and personalisation, clinicians should consider:

* + **Safety** – the balance of benefit and risk. Is the patient experiencing any side effects? Are these excessive when weighed against the benefits of the medicines? Is there any other risk of harm due to co-morbidities (high risk medicines, drug interactions, contraindications)?
	+ **Effectiveness** What is each medicine for, and is that recorded in the patient’s record? Is it appropriate? Is it still indicated? Is it working? Does the patient still take or want it (patient opinion, objective evidence; see shared decision making above)? Are long-term condition(s) well controlled? Should anything be added to treatment?
	+ **Alternatives to medicine** – has the patient been given sufficient information about the available alternatives, which (where appropriate) may not be a medicine, including for example social prescribing?

Appropriate follow-up SMR appointments should be arranged to ensure the safety and effectiveness of any interventions. The clinician undertaking the SMR will determine the number of follow-ups needed in partnership with the patient; this will depend on complexity. It may be that other professionals could follow up the patient. These should be coded as outlined in the appendix.

##### Collaboration on wider medicines optimisation

The national medicines optimisation opportunities dashboard on [ePACT2](https://www.nhsbsa.nhs.uk/epact2) provides data to determine where to focus efforts for the local population. PCNs should be aware of the opportunities that the ICB has prioritised for delivery. PCNs should take into account the [National Medicines Optimisation Opportunities](https://www.england.nhs.uk/long-read/national-medicines-optimisation-opportunities-2023-24/) as part of their medicines optimisation stewardship plans. Due consideration should be given to national and local guidance on [items which should not be routinely prescribed in primary care](https://www.england.nhs.uk/wp-content/uploads/2019/08/items-which-should-not-routinely-be-prescribed-in-primary-care-v2.1.pdf).

PCNs should also support the integration of national-level programmes, such as the, [Net Zero report](https://www.england.nhs.uk/greenernhs/wp-content/uploads/sites/51/2020/10/delivering-a-net-zero-national-health-service.pdf) and [STOMP](https://www.england.nhs.uk/learning-disabilities/improving-health/stomp) (stopping over medication of people with a learning disability, autism or both with psychotropic medicines; [specific resources for PCNs](https://future.nhs.uk/connect.ti/NationalSTOMPSTAMP)) set out in the Long Term Plan. Open data, e.g. Model Health System, [OpenPrescribing](http://www.OpenPrescribing.net),[ePACT2](https://www.nhsbsa.nhs.uk/epact2) and other tools can further support this work.

The NHS BSA Polypharmacy prescribing comparators, the NHS BSA Opioid comparators and the NHS BSA Antimicrobial Stewardship comparators are freely available to all GP practices and ICBs, at GP practice, PCN, ICB and regional level. Developed by the NHS BSA and Health Innovation West of England, they have been shown to help PCNs understand their polypharmacy prescribing in comparison to other PCN and national averages, help identify areas of polypharmacy to prioritise and monitor the impact of any local interventions. Developed with GPs and pharmacists, they have been designed to identify manageable numbers of patients to prioritise for a structured medication review.

Through the increased collaboration across the system and working with ICBs, there is a significant opportunity to support the meeting of global commitments on antimicrobial prescribing to reduce [antimicrobial resistance](https://www.gov.uk/government/publications/uk-20-year-vision-for-antimicrobial-resistance) and the [AMR action plan](https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2019-to-2024).

#### Social prescribing

The DES specification states that it is a key requirement of a PCN to “*provide access to a social prescribing service to those who may benefit, so as to help meet the practical, social and emotional needs that can otherwise affect health and wellbeing*”

To achieve this, a PCN is expected to:

* + either directly employ link workers or subcontract provision of the service to another provider;
	+ make social prescribing service accessible to the whole patient population and able to take referrals from GPs, PCNs and other agencies, such as pharmacies, hospital discharge teams, fire service, job centres, social care services, housing associations, and voluntary, community and social enterprise (VCSE) organisations, as well as self-referrals;
	+ use targeted and outreach approaches to ensure social prescribing services reach people who need them most, such as people in [Core20PLUS5](https://www.england.nhs.uk/about/equality/equality-hub/national-healthcare-inequalities-improvement-programme/core20plus5/) populations;
	+ co-produce with partners (especially Voluntary, Community and Social Enterprises - VCSE) and with people with lived experience;
	+ ensure social prescribing link workers are fully integrated in multidisciplinary teams alongside Health and Wellbeing Coaches and Care Co-ordinators as described in Annex B of the DES specification;
	+ consider developing specialist social prescribing link worker roles to meet local needs, focused on specific cohorts, for example children and young people with mental health needs; people with learning disabilities and/or autism; and people from inclusion health groups
	+ give due regard to the [Social Prescribing Information Standard](https://digital.nhs.uk/data-and-information/information-standards/information-standards-and-data-collections-including-extractions/publications-and-notifications/standards-and-collections/dapb4066-social-prescribing). This will enable PCNs to evaluate the performance of the social prescribing service;
	+ work with partners in the ICS (such as Local Authorities and VCSE) to establish joined up approaches to developing social prescribing and community-based support; and
	+ ensure all link workers to have access to the GP information system used within the PCN and code their work as outlined in the appendix.

##### Cohort selection

A PCN can identify cohorts who would most benefit from social prescribing by working with local partners, using PHM data, health inequalities data (such as the Health Inequalities Improvement Dashboard) and community insights, to identify how best to target social prescribing services.

Social prescribing can be particularly beneficial to people who:

* + have complex social needs (this should include people in Core20PLUS communities);
	+ experience loneliness or isolation;
	+ have multiple long-term conditions;
	+ experience low level mental health issues; and
	+ are [high frequency users of primary, community or urgent and emergency care services](https://www.england.nhs.uk/publication/going-further-on-our-winter-resilience-plans/)..

A further range of tools, resources and case studies can be found on the NHS England [social prescribing webpage](https://www.england.nhs.uk/personalisedcare/social-prescribing/) and [PCN reference guide](https://www.england.nhs.uk/publication/social-prescribing-reference-guide-and-technical-annex-for-primary-care-networks/).

#### Enhanced health in care homes (EHCH)

The DES specification states that it is a key requirement of a PCN to "*d~~e~~liver an Enhanced Health in Care Homes service in accordance with the framework and guidance, including:*

* *agreement with the commissioner for which care homes the PCN is responsible;*
* *identifying a lead GP (or other senior clinician) with responsibility for the implementation of the EHCH framework for the agreed care homes, and to provide continuity of medical care;*
* *co-ordinating an MDT meeting and associated actions, including the lead GP or clinician and care home staff;*
* *delivering a weekly care home round​; and*
* *ensuring accurate coding of care*.”

To achieve this PCNs should follow the [Enhanced Health in Care Homes (EHCH) Framework](https://www.england.nhs.uk/long-read/providing-proactive-care-for-people-living-in-care-homes-enhanced-health-in-care-homes-framework/) which describes the implementation model in detail, describing the inputs and responsibilities across the system, to ensure person-centred integrated care is delivered at the care home level, with an emphasis on multi-disciplinary support and shared care planning.

Additionally, a PCN is expected to:

* support people entering, or already resident in the PCN’s Aligned Care Home, to register with a practice in the aligned PCN if this is not already the case; and ensure a lead GP (or GPs) is agreed for each of the PCN’s Aligned Care Homes. By exception, the clinical lead may be a non-GP clinician with appropriate experience of working with care homes, provided this is agreed by the practices in the PCN, the commissioner and the relevant community provider;
* work with community service providers (whose contracts will describe their responsibility in this respect) and other relevant partners to establish and coordinate a multidisciplinary team (“MDT”); and have established arrangements for the MDT to enable the development of personalised care and support plans, in line with the guidance in the EHCH framework [link];
* identify and engage in locally organised shared learning opportunities as appropriate and as capacity allows; and support with a patient’s discharge from hospital and transfers of care between settings, including giving due regard to NICE Guideline 2756;
* ensure the coding of care home residence is accurately recorded using the relevant SNOMED codes as published in the supporting Business Rules.
1. Enhanced access

Section 8.6 of the DES specification sets out the requirements for delivery of enhanced access.

For enhanced access the Network Standard Hours cover 6.30pm-8pm during the week and between 9am and 5pm on Saturdays. Where a Core Network Practice is required under a General Medical Services (GMS) contract to provide core services at its premises after 6.30pm, the patients of that practice must also have access to enhanced access appointments, and the enhanced access appointments must be in addition to the appointments offered as part of that practice’s core hours service offer.

Core Network Practices within a PCN are collectively responsible for the delivery of enhanced access. In the event the commissioner is not satisfied that a PCN is delivering the requirements in accordance with the DES specification, then the commissioner may take action as set out in section 9 of the DES specification. If a commissioner determines to withhold payment, the amount withheld will be an appropriate proportion of the enhanced access payment and the Core PCN funding payment.

PCNs have the flexibility to sub-contract enhanced access services to other providers in accordance with any sub-contracting provisions of the GP practices’ primary medical services contracts.

In relation to enhanced access, the DES specification sets out the minimum universal requirements for PCNs to deliver. It is expected that, where areas had additional patient services in place locally prior to the introduction of enhanced access in October 2022, commissioners will have made arrangements for these to continue (and any changes would be subject to local engagement). Where levels of capacity or funding as provided under the CCG Extended Access Service at 30 September 2022 exceed the minimum requirements for enhanced access set out in the DES specification, commissioners are expected to ensure these capacity and funding levels under the CCG Extended Access Service are maintained going forward.

#### Delivery of enhanced access

Enhanced Access should be delivered in accordance with the previously developed Enhanced Access Plan that was agreed with the commissioner.

It is up to the PCN to determine the delivery model for enhanced access as part of the Network Agreement, but PCNs will need to ensure this service is offered to the entire PCN population. The exact model of delivery in each PCN may vary and could include:

1. All practices in the PCN offering enhanced access to their own registered list.
2. One practice undertaking the majority of the enhanced access provision for the PCN’s population, with other practices participating less frequently (but those practices’ registered patients still having access to enhanced access at other sites).
3. One practice offering enhanced access to its own registered list and the other practices sub-contracting delivery for their respective patients.
4. The PCN subcontracting delivery as a whole or elements of the service to another provider for its collective population. A PCN may decide to sub-contract delivery of enhanced access and if doing so this must have due regard to the requirements set out in the statutory regulations or directions that underpin each Core Network Practice’s primary medical services contracts in relation to sub-contracting, as set out in section 5.6 of the DES specification.

Irrespective of the delivery model, the PCN should ensure all network patients have access to a comparable enhanced access service offer. PCNs should ensure any sub-contracting arrangements are in accordance with any sub-contracting provisions of the Core Network Practices’ primary medical services contracts.

#### Funding for enhanced access in the Network Contract DES

Enhanced access payments under the DES will be made using PCN Adjusted Populations, which are based on ICB Primary Medical Care allocations weighted populations.

PCNs can view their enhanced access funding here or in the [GP contract ready reckoner](https://www.england.nhs.uk/publication/network-contract-directed-enhanced-service-financial-ready-reckoner).

1. Appendix

### Coding requirements – SNOMED codes

|  |  |
| --- | --- |
| **Heart failure**To use following diagnosis. Knowing these classifications are important precursors to defining the appropriate evidence-based treatment. | * HF with reduced ejection fraction– code as HFREF: 70327200
* HF with mildly reduced ejection fraction – code as HFREF:788950000; and
* HF with preserved ejection fraction – code as HFPEF: 446221000
 |
| **Social Prescribing**To use following social prescribing offer  | * + - 871731000000106 – Referral to social prescribing service (procedure).
		- 871711000000103 – Social prescribing declined (situation);
 |
| **Proactive Care** To use in relation to commencement or ending of Proactive Care – supports the measurement of percentage of registered patients under the provision of Proactive Care [PR001]; and Percentage of registered patients discharged from Proactive Care service [PC003] using the count related clinical codes: | * 934231000000106 Provision of proactive care (regime/therapy)”; and
* 934691000000105. Proactive care ended (situation)”
 |
| **SMRs** To use in the administration of an SMR, or a follow up  | 1239511000000100 Structured Medication Review (procedure)  |